Nitric oxide synthase (NOS), an enzyme responsible for the production of NO, is found in large quantities in prostatic diseases, particularly in malignancy, and may play an important role in the pathogenesis of these diseases. A chemopreventative role in prostate cancer has been suggested by in vitro studies of NSAIDs. New generation NO-NSAIDs combining the effects of both have been created and here we present our findings with these in prostate cell systems.
Introduction
Androgens play a major role in prostate carcinogenesis and proliferation of androgen in the prostate is mediated by the Androgen receptor (AR). The AR binds androgen then recognizes and binds the Androgen Response Element (ARE) in the promoter region of androgen regulated genes. As PSA levels are elevated in any condition that increases prostate size it is proposed that a substitution polymorphism (G/A) in the PSA/ARE may interact differently with the AR and be important in prostate cancer risk.
Patients & Methods
This was a study of 100 prostate cancer patients aged 50-75yrs from urology departments and an age-matched cohort of 79 BPH and 67 population controls. DNA was extracted from blood and PSA/ARE promoter region amplified by PCR.
PCR products were cut with Nhe 1 restriction enzyme and resolved on 1.5% agarose gels to distinguish alleles. AR/CAG repeat length was detected by automated fluorescence Results We found GG genotype to be linked to status subjects with this genotype had a small increased risk of prostate cancer. However younger men <65 had a significantly higher risk of prostate cancer (P = 0.02) when homozygous for the G allele. Furthermore when cross-classified with the AR polymorphism men carrying short (<22) CAG/GG genotype had a x4 increased risk (P = 0.006) of malignant disease.
Conclusion
Our results indicate that the PSA/ARE GG genotype confers an increased risk of prostate cancer especially among younger men. Moreover a short glutamine repeat in conjunction with GG genotype significantly increases the risk of malignant disease.
Introduction
Although biofeedback-assisted pelvic floor exercise (PFE) is reported to be effective in the management of post-radicalprostatectomy incontinence, randomised, controlled trials have not shown any significant advantage for its use. The reports were however small, single centre studies. Electrical stimulation (ES) in men with urinary incontinence remains a research tool. We surveyed the involvement and practice of UK physiotherapists in the management of post RP men.
Materials and Methods
A six-item questionnaire was mailed to the physiotherapists in charge of 96 departments in the British Isles where radical prostatectomy (RP) is performed in the corresponding urology departments. The questionnaire elicited whether RP patients were referred before or after surgery by their urologists, and whether they used biofeedback and/or electrical stimulation (ES), and their schedule of treatment. Optional provision for comments was made. Results Seventy-seven physiotherapists responded (80%). Of these, 52% received RP referrals, which were made postoperatively in 80%, and the rest preoperatively. 70% of referrals were for prolonged incontinence patients. 50% of those receiving referrals have biofeedback facilities, and 38.5% incorporate it in their management regime of RP patients. Only 22.5% use electrical stimulation.
Conclusion
The level of physiotherapist participation in the multidisciplinary management of RP patients appears to fall short of expectation for various reasons. Majority does not use biofeedback techniques. The effect (if any) of these findings on the quality of service to these patients is unknown. Good evidence to guide practice is needed.
Introduction
Following radical prostatectomy, the urethral catheter is commonly removed at 2 to 3 weeks. The clinical significance of anastomotic leaks is unclear but may lead to significant morbidity in the intermediate and long term. If a leak were to be detected, it is unclear if delaying catheter removal provides any clinical benefit. Patients and Methods 41 patients underwent a cystogram at 3 weeks and had a rigid cystoscopy on the same day to evaluate the presence of a leak or defect. 17 patients had their catheter removed at 2 weeks without any investigation to assess the anastomosis. Result 3 patients had defects at cystoscopy and 9 leaks identified on cystography (including the 3 noted at cystoscopy). Two patients developed strictures and neither had any significant leaks or defects. Out of the 17 who had their catheters removed at 2 weeks without any investigation, 1 had a urinary fistula and 1 developed a stricture. There were no statistically significant differences between the two groups. Conclusion Assessment of the vesico-urethral anastomosis using cystography or cystoscopy appears to be redundant in the management of patients following radical prostatectomy as it does not influence the clinical course of events. The decision to postpone catheter removal can be made on clinical grounds.
GLUT-1 is a glucose transporter that is upregulated in many human solid tumours as a consequence of biochemical adaptations to hypoxia. Recent studies have demonstrated that GLUT-1 expression is a marker for poor prognosis in carcinoma cervix. Aims To examine the expression of GLUT-1 in human prostate cancer and its relation with disease progression and patient survival.
Methods
Formalin fixed paraffin embedded paired human specimens of 19 prostate cancer patients were selected. Each pair of tissue consisted of hormone sensitive and refractory prostate cancer collected from the same patient as their disease progressed. Sections were stained for GLUT-1 and scored by three independent investigators for extent & intensity of staining. Two prostate cancer cell lines (DU145, PC3) were subjected to hypoxia & immunostained.
Results
Nine specimens in the hormone sensitive group and seven specimens in the hormone refractory group stained positively (>20%cells) for GLUT-1. Intensity of staining was variable & average Gleason grade was 8. In all the cell lines GLUT1 was upregulated in hypoxia. The average time of positive GLUT-1 specimens to progress from hormone sensitive to refractory was 2.5 years compared to 5.5 years in the non GLUT-1 staining group. GLUT-1 positive specimens in the hormone refractory group died of metastatic disease with an average time of 11 months. Among GLUT-1 negative specimens in hormone refractory group (n = 12), one patient died of metastatic disease at 14 months. The rest were alive at eighteen months follow up. Conclusion Although the expression of GLUT-1 in paired specimens of human prostate cancer was variable, GLUT-1 is upregulated in hypoxia & its expression in prostate cancer is associated with tumour aggressiveness, rates of disease progression and patient survival.
Introduction
Oxidative stress contributes to the nutritional decline of cancer patients. The basis of this oxidative stress could either be due to the tumour itself or a host response. The polyunsaturated fatty acids are extremely sensitive to oxidation. The major product of lipid peroxidation is malondialdehyde (MDA). We examined the relationship between lipid peroxidation (malondialdehyde), the relationship between lipid soluble vitamins (Į-tocopherol, lutein, lycopene, Į-carotene, ȕ carotene, host systemic inflammatory response (C-reactive protein) and stage of disease in patients treated for prostate cancer.
Patients and methods
Patients with BPH (n=19), localised (n=32) and metastatic (n=39) prostate cancer were studied. Blood samples were removed for the measurement of PSA, CRP, MDA, cholesterol, Lutein, Lycopene, and Carotenes. MDA concentrations were adjusted for cholesterol. The local ethics committee approved the study.
Results
Increased MDA concentrations were associated with more advanced stage of disease and reduced lutein and lycopene concentrations. In contrast, there was no significant alteration in the other lipid soluble vitamins or C-reactive protein. 
Audit of an audit: validation of the Yorkshire regional radical prostatectomy database S. Basu

Introduction
To gain meaningful results from a database it is important to monitor the quality of data entered. This audit aims to verify the accuracy of our prospective database by an independent observer Methods Consultant Urologist from a neighboring hospital was invited to randomly select 25% of patients from the database and crosscheck the database entries with the clinical notes. All the discrepancies were documented, any results that could not be verified were marked as discrepant. Results At present, HIFU is being investigated for the treatment of localised prostate cancer (PCa) (T 1-2 , N x , M 0 ). Clinical trials evaluating "whole gland" ablation are in progress using transrectal devices that integrate HIFU with separate diagnostic ultrasound for image guidance. Despite provisional results challenging those obtained from radiotherapy, residual neoplasm has been identified in the treatment margins of some patients. This may stem from transrectal ultrasound (TRUS) imaging of PCa being neither sensitive nor specific. Magnetic Resonance (MR) imaging, utilising an endorectal receiver coil, correlates directly with pathological findings and is the radiological "gold standard" for detecting extracapsular extension. We have therefore incorporated this superior imaging modality with a HIFU transducer to create a transrectal device capable of mapping and ablating PCa.
Materials And Methods
A transrectal HIFU transducer, designed for optimised tissue destruction, with an MR endocoil around its periphery was evaluated in a 1.5 Tesla MR scanner. To minimise MR image artefact the conductive transducer surface was quartered into equal sized electrically isolated areas. The HIFU field profile was measured and the spatial peak intensity calibrated as a function of electrical power. The morphology and extent of HIFU induced tissue necrosis was investigated in ex-vivo tissue studies.
Results
Dividing the transducer surface significantly decreased induced eddy currents and improved the homogeneity and signal-to-noise ratio of the MR image (by ∼35%). The threedimensional acoustic field profile demonstrated a "cigarshaped" HIFU focus of 10.2 x 3.0 x 1.4mm (-6dB). At 70W the free-field spatial peak intensity was 3100W/cm 2 . In ex-vivo tissue clearly delineated lesions, 8.1 x 1.7 x 1.3mm (± 6.5%), were created at this power with 5 second exposures. Conclusion An integrated transrectal device capable of yielding highresolution MR images and producing controlled and reliable tissue necrosis has been constructed. MR-guided transrectal HIFU has the potential of becoming a viable alternative to current "curative" therapies for organ-confined PCa and a first-line treatment for patients with local relapse postradiotherapy. The above research has ethical approval for the proposed clinical studies at Hammersmith Hospital, London. The research has been funded by a Department of Health NEAT grant.
Introduction
The matrix metalloproteinases (MMPs) are a family of 24 human endopeptidases many of which have been implicated in tumourigenesis. Apart from MMPs 2,7 and 9 little is known of the contribution of this family of proteases in prostate cancer. Of the tissue inhibitors of metalloproteinases (TIMPs), only TIMPs 1 and 2 have been studied whereas the role of others is unknown. Methods Having established a validated human fresh frozen prostate tissue bank of over 150 benign and malignant prostate tissues, we extracted RNA from many of these tissues and reversed transcribed it. We have applied TaqMan real-time RT-PCR to quantify levels of expression of these genes in 50 cases of prostate cancer and 22 cases of benign prostate tissue. This pilot study explored the feasibility of intermittent LHRH agonist as first-line therapy for metastatic prostate cancer.
Method
Patients had either positive bone scan or PSA >100 and were eligible if after 6 months of monthly leuprolide PSA <4 and testosterone <2nmol/l. Hormone therapy was discontinued until PSA 15 when monthly leuprolide was re-started. Testosterone, PSA and pain score were assessed monthly. Cycles were repeated if the above criteria for PSA were met. Twenty-five patients were recruited over a 3-year period. The median follow-up is 14 months. Result Three patterns have been identified: Pattern A (10/25), a rise in testosterone to >5nmol/l was followed by a rapid rise in PSA to 15 in 4 months (median 1 month); Pattern B (10/25), PSA rise >4 months after the testosterone >5nmol/l (median 10 months, range 5-18). In 4/10 PSA has yet to rise above 15; Pattern C (5/25), testosterone remained <5nmol/l after 6 months leuprolide yet PSA rose to 15 at a median 3 months after stopping hormone therapy (range 2-14 months) and all 5 became hormone resistant. Hormone resistance, defined as rising PSA despite re-starting leuprolide, occurred in 7, 2 pattern A and all 5 pattern C. Bone pain scores were low. Conclusion 80% of patients followed the expected rise and fall of PSA related to testosterone but within a wide range of time from 1 to 23 months after entering the study. Whether the additional time required monitoring intermittent treatment is worthwhile must await the results of ongoing randomised trials. 
32
P post labelling showed DNA adducts in the range of 17 to 1280 for B(a)P, 5 to 461 for IQ and 9 to 23 for PhIP(adducts/10 10 nucleotides). Cytochrome P450 a phase I enzyme, N-acetyl transferase(NAT) a phase II enzyme are differentially expressed in prostate compared to muscle by a factor of two. Immunohistochemical staining localised NAT enzymes to prostate epithelial cells but not to stroma. Conclusion Prostate expresses key xenobiotic metabolising enzymes and activates dietary carcinogens to form DNA adducts. The resulting DNA adducts can lead to mutation and cancer. We are at present in the process of delineating the key metabolic pathways of activation of these carcinogens.
Introduction
Insulin-like growth factors (IGFs) stimulate cell proliferation and are associated with increased cancer risk. Insulin-like growth factor binding proteins (IGFBPs) oppose this effect by binding IGFs and also inhibiting growth directly. Indeed in normal prostates the glandular involution which occurs on androgen withdrawal is associated with increased IGFBP-5 expression. Here we demonstrate that IGFBP-5 can also function as growth factor in prostate cancer but the effect differs according to the androgen sensitivity of the cells.
Materials and Methods
Androgen sensitive (LNCaP) and androgen insensitive (PC-3 and DU145) prostate cancer cells were treated with IGFBP-5 (25-200 ng/ml) for 24 hours. DNA synthesis was measured with a pulse labelled tritiated thymidine uptake assay to indicate cell proliferation. Western immuno-blotting was performed for cell cycle regulators p21 and p27. Results IGFBP-5 caused a dose dependent increase in tritiated thymidine uptake (up to 30% above control) and reduced p27 expression in LNCaP cells. IGFBP-5 caused a dose dependent reduction in tritiated thymidine uptake (up to 25% below control) and increased p27 expression in PC-3 and DU145 cells. P21 expression was unaffected.
Conclusion
These results suggest that in prostate malignancy IGFBP-5 acts as a growth factor. This pathway may utilise the androgen receptor as the phenotype was reversed in androgen insensitive cells. The cell cycle inhibitor p27 is likely to be implicated since it was reciprocally regulated according to the growth response to IGFBP-5. Further understanding of the role of IGFBPs in prostate cancer and androgen resistance may yield novel therapies and prognostic information.
Expression Pattern of the ADAMTS Proteinases In Human Prostate Cancer Cell Lines
Chandrasekharan S, Cross NA, Holen I, Hamdy FC, Buttle DJ.
Department of Urology, University of Sheffield, Sheffield, UK
Introduction and Objectives
Cancer invasion requires the breakdown of basement membranes at an early stage, as well as angiogenesis, which is essential for tumour growth and haematogenous spread. The ADAMTS enzymes, named because of their structure and function (A Disintegrin And Metalloproteinase with ThromboSpondin motifs) modulate tumor growth, inhibit angiogenesis and are thought to be involved in metastases formation. Our objective was to study the differential expression of a selected subgroup of these enzymes in human prostate cancer cell lines. Materials and Methods 3 prostate cancer cell lines were used, androgen independent PC-3 and DU145 lines, and the androgen dependent LNCaP line. Cells were grown to confluence using standard medium, then RNA extracted and expression studied by RT-PCR using custom designed primers. PCR products were purified and sequenced to ensure that the appropriate product was identified. Results ADAMTS -5, 9 and 15 are only expressed by the hormone independent prostate cancer cell-lines PC-3 and DU145, while ADAMTS-1 and 4 are expressed by both as well as the androgen-sensitive LNCaP cells. ADAMTS-8 expression was not demonstrated in any of these cell lines.
Conclusion
To date, there have been no prior published studies investigating ADAMTS enzyme expression in prostate cancer. The differential expression of these enzymes in vitro suggests that whilst angiogenesis inhibiting ADAMTS-1 and 4 may limit aggressive behaviour of the cells -a well know feature of LNCaP cells, over-expression of ADAMTS-5, 9 and 15 may contribute to the hormone resistant phenotype. Real-time PCR for quantification and androgen suppression experiments are in progress.
Introduction
Transforming growth factor beta1 (TGFb1) and Fibroblast growth factor 2 (FGF2) are autocrine regulators in prostatic stroma, both shown to be elevated in benign prostatic hyperplasia relative to normal prostate tissue. In vitro studies have suggested that TGFb1 may regulate the availability of FGF2 in prostatic stromal cells. In this study, the effects of FGF2 and TGFb1 on TGFb1 bioavailability and extracellular matrix production were studied in prostatic stromal cells using defined, serum-free culture conditions.
Materials and methods
Growth experiments were performed on a series of three prostatic stromal cell cultures challenged with TGFb1 and/or FGF2 in serum free medium. RNA isolated from cells challenged with growth factors was used to evaluate relative transcript levels of growth factors, Type 1 Collagen and matrix metalloproteinases (MMPs) by duplex and real-time RT-PCR. Western blotting was used to detect Type 1 Collagen synthesis and growth factor expression was determined by ELISA. Results Prostatic stromal cell growth under serum free conditions was dependent on the presence of FGF2. FGF2-induced growth was abrogated by the addition of 5ng/ml TGFb1. Real-time RT-PCR demonstrated that challenge with TGFb1 increased TGFb1, FGF2, Type 1 Collagen and MMP2 mRNA. FGF2 also increased TGFb1 mRNA and ELISA data demonstrated that FGF2 increased TGFb1 secretion. Type 1 collagen synthesis was increased by TGFb1 stimulation whereas FGF2 opposed this action. Conclusions FGF2 and TGFb1 have opposing actions on growth and ECM synthesis in prostatic stromal cells. Their mutual induction may represent a negative feedback mechanism controlling stromal proliferation and differentiation.
Quantifying the need for palliative care in patients with prostate cancer within a urological unit R Singh, A Putnis, R Brierly and TS O'Brien Guys Hospital, London
Introduction
The number of deaths ascribed to prostate cancer rises year on year. Many patients with advanced prostate cancer might benefit from specialist palliative care. This study aimed to quantify the number of patients and characterize the nature of the problems that occur.
Methods
The study was divided into two parts over a four-month period. All in-patient episodes were recorded prospectively whilst outpatients were identified retrospectively by review of all outpatient correspondence during the study period. Patients were identified as potentially needing palliative care if they had hormone relapsed disease. Results 795 cancer related outpatient consultations were reviewed. They included 578 prostate cancer episodes. From these 56 episodes for 45 patients met our criteria for a palliative care consultation -representing 10% of all prostate cancer consultations. In 13/45 no intervention was required. In 32/45 palliative symptoms needed to be addressed. These included: bone pain (14/32), renal failure/hydronephrosis (6/32), haematuria/ anaemia (6/32), UTI/LUTS (3/32), lymphoedema (2/32) and general malaise (4/32). A total of 27 in-patient episodes for advanced urological malignancy were recorded including 10 episodes for prostate cancer. These included: retention (2), haematuria/anaemia (6), pneumonia (1), possible cord compression (3), renal failure/hydronephrosis (2) and general malaise (1).
Conclusions
Patients requiring palliative care for advanced prostate cancer place a significant burden on urological inpatient and outpatient services. There is a case for specialist palliative care within the urological service. Urologists need to be trained in palliative care as it comprises a significant proportion of their work. 
PSA
Result
Median follow-up was 52 months for the remaining 611 patients. Median PSA was 9.8 mcg/l. Overall Kaplan Meier PSA recurrence free survival probability at 1, 3 and 5 years was 0.83+/-0.02, 0.69+/-0.02 and 0.60+/-0.03, respectively. 5 year PSA recurrence free survival probability for PSA ranges <4, 4.1-10, 10.1-20 and >20 was 0.82+/-0.08, 0.73+/-0.05, 0.58+/-0.05 and 0.20+/-0.07, respectively (Wilcoxon P < 0.0001). PSA recurrence free survival probability for biopsy Gleason grade 2-4, 5 and 6, 7 and 8-10 at 5 years was 0.65+/-0.07, 0.61+/-0.04, 0.54+/-0.09 and 0.23+/-0.12, respectively (Wilcoxon P < 0.0001). Similarly, 5 year PSA recurrence free survival probability for clinical stages T1a and 1b, T1c, T2a and T2b was 0.79+/-0.09, 0.64+/-0.06, 0.59+/-0.05 and 0.44+/-0.09, respectively (Wilcoxon P = 0.0012). Conclusion PSA recurrence free survival estimates are less optimistic compared to frequently quoted American figures. These figures may help to counsel British patients prior to radical prostatectomy and seem to reflect a more realistic expectation following surgery in the UK.
Introduction
The significance of Prostatic Intraepithelial Neoplasia (PIN) as a precursor to cancer has been the subject of many discussions due to our lack of understanding of its natural history.
One study demonstrated a significant correlation between high grade PIN and prostate carcinoma. Although LHRH agonist is an established primary treatment for prostate cancer, little is known of its effect on PIN. A decrease in PIN in radical prostatectomy specimens following androgen deprivation has been noted. This study is to document our experience. Methods From 1994 to 2002, 25 patients received preoperative androgen blockade (LHRH agonist :23 patients, antiandrogens:2 patients) prior to radical prostatectomy at this institution. These cases were reviewed and the PIN was mapped, described and compared to previous biopsies where available. Results 17 had biopsies undertaken or reviewed here and of these 11 showed PIN in both prostate biopsies and prostatectomy specimens. Three had PIN in the biopsies but none was identified in the prostatectomy specimens. Where PIN was easy to find, the architectural and nuclear features remained unchanged, but in equivocal areas the glandular infoldings appeared flattened. The cells were smaller with less cytoplasm, the chromatin was vesicular, there was reduced nuclear to cytoplasmic ratios and the nucleoli were less prominent. Conclusion Androgen blockade decreases the incidence and extent of PIN and also changes the architectural and nuclear features of PIN, making it more difficult to identify. As PIN can be the sole finding in needle biopsies, this observation raises the possibility of androgen ablation as an option in selected patients for cancer chemo-prevention.
Predicting patients at high risk of biochemical failure after radical prostatectomy (RP) using pre-operative parameters enables us to optimise patient selection. Most patients with a pre-treatment PSA of >10 mcg/l are advised against RP on the basis of high biochemical failure rates in the US. Patients with a PSA of >10 mcg/l are still elected to have RP in the UK. Pathological data for those who elect for surgery can further stratify patients at greatest risk of PSA relapse. The role of perineural invasion (PNI) in this regard remains unclear on multivariate analysis but seems to be useful on univariate analysis. Recently the maximum diameter of PNI, as opposed to its mere presence, has been shown to be an independent variable to predict PSA relapse following radical prostatectomy. The purpose of this study was to examine the association of pre-operative parameters and the role of the maximum diameter of PNI in predicting patients who would be at risk of early biochemical failure in a UK population.
Methods 259 patients underwent RP over a 9-year period in our institution. Biochemical failure was defined as three consecutive PSA rises above 0.4 mcg/l. All patients who received neo-adjuvant or adjuvant treatment were excluded from the original cohort. 31 patients who had documented PNI at RP had the maximum diameter of PNI recorded retrospectively to analyse if future PSA failure could be predicted by this parameter.
Results
Median PSA was 13.5 mcg/l. Kaplan-Meier survival probabilities at 1,3 and 5 years were 0.92 +/-0.02, 0.82 +/-0.04 and 0.70 +/-0.07 respectively for the entire cohort. Only PSA and biopsy grade were significant pre-operative predictors of biochemical failure (p=<0.0001 and p=0.0043, respectively) on multivariate analysis. Kaplan-Meier survival probabilities at 5 years for patients with a PSA < 10 mcg/l and >10 mcg/l were 0.89 +/-0.07 and 0.34 +/-0.12, respectively (log rank P < 0.0001, HR 0.1 CI 0.04 to 0.24). Median time to PSA recurrence for patients with a PSA >10 mcg/l was reached at 48.4 months (CI 45.08 to 51.72). On a univariate Cox proportional hazards regression model perineural invasion diameter was associated with disease recurrence but this was not seen in the multivariate analysis.
Conclusion
Patients with a PSA > 10 mcg/l have a very poor 5-year PSA recurrence free survival estimate of 34% in the UK. This raises the question whether such patients should be offered radical prostatectomy. In addition, in our study the maximum diameter of PNI was a significant predictor of disease recurrence on univariate analysis but due to a small sample size this was not borne out on a multivariate analysis. Further work on a larger sample size is needed to see if this is an independent explanatory variable for PSA failure.
Introduction
Although long-term urinary toxicity from conformal prostatic radiotherapy appears limited, there remains a strong clinical impression of a transient increase in urinary symptoms during radiotherapy. However, the immediate effects of conformal radiotherapy on International Prostate Symptom Score (IPSS) and bladder function are unknown. Methods 24 patients were recruited into an observational study in which lower urinary tract function was assessed before, during, and immediately after conformal radiotherapy for localised prostate cancer. IPSS scores, urinary flow rate (Qmax) and post-micturition residual (PMR) volumes were recorded before and then weekly during the treatment course. IPSS was again recorded at four and eight weeks following treatment.
Results
Mean total IPSS rose in a time dependent manner from 9.75 pre-treatment to 20.2 at the end of radiotherapy. 50% of patients developed "severe" urinary symptoms by IPSS classification, with a further 45% having "moderate" Introduction BPH is one of the commonest conditions seen by urologists. Retro-pubic Prostatectomy (RPP) is considered the treatment of choice for large prostates but the procedure seems to be performed less often. The authors believe that this operation is important, as exposure of the prostate is needed if packing of the prostate is required for excessive bleeding during TURP. A national survey of specialist registrars (SpR) training in urology in the UK was carried out to ascertain what exposure and experience they received and to what extent they thought they had adequate training. Methods A postal survey was sent to all SpR's on the training database. They were asked how many RPP they assisted and performed. They were also asked how they would treat a 120cc prostate and whether they would be confident performing a RPP
Introduction
Haematuria is a relatively common condition and is often diagnosed as secondary to BPH when investigations are negative. There doesn't appear to be a generally accepted schedule of investigations. Finasteride, even though not licensed for the treatment of haematuria of prostatic origin, has been shown to be effective. The authors carried out a survey to ascertain current work practices. Methods A national postal survey of all consultant urologists on the BAUS directory was undertaken. They were asked to complete a questionnaire examining how they investigated and managed haematuria and whether and when they used finasteride.
Result
There were 212 responses out of 515 sent (41%). 81% run a haematuria clinic at which 69% allowed direct GP referral.
Comparing microscopic versus macroscopic haematuria, ultrasound was used 65% v 25%; IVU was used 15% v 24% and both modalities were used 20% v 51%. Routine use of urine cytology was undertaken by 58% of respondents while 62% would take biopsies and 52% treat small bladder tumour recurrences with a flexible cystoscope. If investigations are normal, 88% discharge for microscopic and 53% for macroscopic haematuria. 98% treat intermittent haematuria of prostatic origin with finasteride, with 57% using it indefinitely. With regard to pretreating patients undergoing TURP with finasteride, only 4% pretreat all patients, while overall 51% use it in certain cases -urethral catheter in situ: 7%; intermittent haematuria: 35%; prostate >40g: 24%; poor cardiac reserve: 14%; suspect may bleed: 21%.
Conclusion
This survey highlights the different approaches to investigating haematuria and the large use of finasteride for haematuria.
Introduction
Since February 1997 we have run an early prostate cancer (EPC) clinic adopting a multi-disciplinary approach to the management of this malignancy. We report on our first 6 years experience using this approach. 
Patients and methods
Introduction
The Hospital Anxiety and Depression Scale (HADS) is a well validated 14-item scale specifically designed for patients with medical illnesses, as it excludes somatic items and relies only on emotional symptoms of depression and anxiety. We compared the HADS scores of men attending their first outpatient appointment for either erectile dysfunction (ED) or early prostate cancer (EPC) to assess the level of psychological difficulties in these patient groups.
Method and Patients
Consecutive referrals awaiting their first consultation (n=236) were requested to complete the HADS questionnaire prior to being seen by a clinician after obtaining informed consent. One hundred and fifty patients were investigated for ED and 86 for EPC.
Results
The ED group had a mean age 58 years (range 18-82) compared to a mean age of 64.5 years (range 48-78) for the EPC group. Using a score of 11 or greater out of 21 for each subscale (anxiety or depression) to indicate 'caseness' (a term used to describe a level of psychological distress that is believed to be clinically significant) we found that the level of anxiety in the ED group (20%) was more than twice that of the EPC group (9.6%). The ED group also scored a higher level of 'caseness' on the depression subscale.
Conclusion
Our study demonstrates that clinically significant levels of psychological distress are greater in ED patients than EPC patients and one should not assume that psychological distress is greater in cancer sufferers than non-cancer sufferers at presentation. 
Introduction
Neo-angiogenesis plays a vital role in the growth, progression and metastasis of many cancers. One mechanism proposed for the induction of neo-angiogenesis is via the induction of the cyclo-oxgygenase-2 enzyme (COX-2), and its products. COX-2 expression itself is also associated with poor prognosis in prostate cancer and has been implicated in the pathogenesis of several human cancers. We tested the hypothesis that angiogenesis in prostate cancer is associated with increased COX-2 expression.
Materials and Methods
Prostate tumours were subdivided into 2 groups by stage (T1/2 and T3/4) with BPH specimens as control. Two further subgroups with metastasis at diagnosis were also studied. Immunohistochemistry (IHC) for the endothelial antigen CD34 was used to determine tumour microvessel density (MVD), a marker for angiogenesis, in 114 patients. Sections were also stained for COX-2 expression by IHC.
Results
There was no significant difference in MVD between tumours (all stages combined) compared to BPH (p=0.22), nor with T3/4 tumours compared with T1/2 (p=0.95). In addition, no significant differences were seen between patients with or without metastasis at diagnosis (p=0.77) irrespective of tumour stage. No correlation was seen between tumour MVD and Gleason score (p=0.40).
No correlation was seen between COX-2 and MVD as measured by CD34 in this study. COX-2 was seen to increase with tumour stage as discussed elsewhere (Abstract by Edwards et al).
Conclusion
Tumour angiogenesis as determined by MVD estimation in this study is not associated with COX-2 expression. Therefore COX-2 may influence tumour progression via inflammation or other mechanisms. 
This novel user-friendly system shows great potential in the management of prostate out patients. Some tuning is needed, with particular respect to uroflow results.
Results
A statistically significant negative correlation was seen between the proportion of SM (%SM) and dynamic modulus (E*) (see Yang et al, Part 1) within all chips. A stronger statistically significant negative correlation was seen between %SM and E* when considering only chips composed purely of stromal tissue, and when considering only chips composed of both stroma and glands.
Conclusions
The morphology of prostatic tissue has an influence upon its mechanical properties. As dynamic modulus is a measure of tissue stiffness these results indicate that prostatic tissue containing more smooth muscle may be more compliant. Further investigation of this relationship and the influence of other tissue components is indicated.
Introduction
Serum prostate specific antigen measurements as a marker for the early detection of prostate carcinoma are unreliable.
Therefore, other biomarkers for the early detection of prostate carcinoma are needed.
Materials/ Methods
Using 2 dimension gel electrophoresis followed by MALDI-TOF-MS fingerprint analysis, we investigated the protein profiles of prostatic fluid expressed in the urine following digital rectal examination, from 6 patients with prostate carcinoma and 6 patients with benign prostatic hyperplasia (BPH).
Results
The mean number of protein spots/ gel was lower in fluids from cancer patients (mean= 140 spots), compared with BPH (mean= 158 spots), however this was not significant. The vast majority of proteins were not seen to be common amongst the two patient groups. Only 20 protein spots were found to be common amongst the 2 patient groups. MALDI-TOF-MS analysis identified 8 of these proteins as alpha-enolase, clathrin (light polypeptide A), isocitrate dehydrogenase, beta-2-microglobulin, alpha-1-microglobulin, complex-forming glycoprotein HC, PRO2675, PRO2044. Five protein spots were seen exclusively in a subset (2 or more) of patients with cancer, but not in any of the fluids from BPH patients. One of these protein spots seen in 4/ 6 patients with cancer but in 0/ 6 patients with BPH, was identified as Calgranulin B.
Conclusion
Our data demonstrate that 2 dimension gel electrophoresis followed by MALDI-TOF-MS analysis is a useful strategy to identify candidate biomarkers for prostate cancer.
